Clinical trial · Observational
Soluble B7-H3 as a Biomarker for Osteosarcoma
An Exploratory Research of Soluble B7-H3 Expression in Peripheral Blood as a Biomarker to Monitor Therapeutic Effect of Systemic Treatment for Osteosarcoma
NCT05942456CI-TRIAL-00077147unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Increasing data has indicated an association between increased soluble B7-H3 (sB7-H3) levels and unfavorable prognosis in patients with malignancies. However, the level of sB7-H3 and its clinical significance in osteosarcoma are not well known. In this present study, we investigated whether sB7-H3 levels in serum could be as a biomarker for osteosarcoma treatment.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Biomarker | — | UNRESOLVED | — |
| Osteosarcoma | Osteosarcoma | ONTOLOGY_EXACT | 0.90 |
| Progression | — | UNRESOLVED | — |
| Surveillance | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| ELISA: enzyme-linked immunosorbent assay | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- sB7-H3 of treatment-naive osteosarcoma patients
- description
- Before delivering neoadjuvant chemotherapy, using ELISA to test the protein expression of sB7-H3 of Peripheral Blood
- interventionNames
- Diagnostic Test: ELISA: enzyme-linked immunosorbent assay
- label
- sB7-H3 after neoadjuvant chemotherapy for osteosarcoma patients
- description
- After neoadjuvant chemotherapy and before definitive surgery, using ELISA to test the protein expression of sB7-H3 of Peripheral Blood
- interventionNames
- Diagnostic Test: ELISA: enzyme-linked immunosorbent assay
Primary outcomes (1)
- measure
- correlation of quantity of Protein B7-H3 Expression with clinical evaluation
- timeFrame
- 6 months
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 12 Years
Show eligibility criteria text
Inclusion Criteria: * High Grade osteosarcoma verified with pathologic diagnosis. * systemic treatment-naive before the first time Blood drawing. * ECOG 0 or 1 and all the other imagings indicate that patients could tolerate standard PKUPH-OS-02 protocol neoadjuvant chemotherapy. * All radiographs are complete for clinical evaluation. Exclusion Criteria: * Patients who Can't tolerate blood drawing. * Patients without complete medical records in PKUPH system. * Patients who can't tolerate PKUPH-OS-02 neoadjuvant chemotherapy. * other conditions that investigators think are not suitable for this study.
References
Publications (2)
- BACKGROUNDWang L, Kang FB, Zhang GC, Wang J, Xie MF, Zhang YZ. Clinical significance of serum soluble B7-H3 in patients with osteosarcoma. Cancer Cell Int. 2018 Aug 13;18:115. doi: 10.1186/s12935-018-0614-z. eCollection 2018. PMID 30123093
- BACKGROUNDXie L, Chen C, Liang X, Xu J, Sun X, Sun K, Yang R, Tang X, Guo W. Expression and Clinical Significance of Various Checkpoint Molecules in Advanced Osteosarcoma: Possibilities for Novel Immunotherapy. Orthop Surg. 2023 Mar;15(3):829-838. doi: 10.1111/os.13620. Epub 2022 Dec 15. PMID 36519392